Zobrazeno 1 - 10
of 48
pro vyhledávání: ''
Autor:
Karen Kelly, Everett E. Vokes, Jonathan W. Goldman, Rebecca S. Heist, Apurvasena Parikh, D. Ross Camidge, J. Wu, Minal A. Barve, Bruce A. Bach, Eric Angevin, Zhaowen Sun, David S. Hong, Philip Komarnitsky, John H. Strickler, Todd M. Bauer, Daniel Morgensztern, Monica Motwani
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(21)
Purpose: Telisotuzumab vedotin (Teliso-V) is an anti–c-Met–directed antibody–drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules
Autor:
Chia-Chi Lin, Timothy A. Yap, Anna M. Szpurka, Maria de Miguel, Xiaojian Xu, Shelly Schmidt, Kay Hoong Chow, Antoine Italiano, Yumin Zhao, Yung Jue Bang, Michelle Carlsen, Wu Chou Su, Hyun Cheol Chung, Amita Patnaik, Burkhard Vangerow, Johanna C. Bendell, Danni Yu, Leena Gandhi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(5)
Purpose: This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib
Autor:
Jeffrey G. Supko, Joaquim Bellmunt, Lauren C. Harshman, Zijie Sun, Mark Pomerantz, Kathryn P. Gray, Atish D. Choudhury, Zachary J. Melnick, Christopher Sweeney, Channing Yu, Philip W. Kantoff, Mary-Ellen Taplin, Meredith M. Regan, Abhishek Tripathi, Sandy Srinivas
Publikováno v:
Clin Cancer Res
Purpose: Androgen receptor (AR) inhibition can upregulate c-MET expression, which may be a resistance mechanism driving progression of castration-resistant prostate cancer (CRPC). We conducted a phase I trial investigating the safety and pharmacokine
Autor:
Ryohei Katayama, Giorgio Senaldi, Pasi A. Jänne, Yanfei Gao, Kyriakos P. Papadopoulos, Erkut Borazanci, Naoki Nakao, Alexa B. Schrock, Masaya Tachibana, Alice T. Shaw, Thomas Yang Sun, Qinying Zhao, Kenji Nakamaru, Heather A. Wakelee, Chenhui Deng, Yuki Shimizu, Sai-Hong Ignatius Ou, Takeshi Isoyama, Viola W. Zhu, Hiroyuki Hanzawa, Meijing Li, Russell Madison, Takashi Seto, Frank Fan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(18)
Purpose: Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against ROS1 G2032R solvent-front mutation among others. We report the first-in-human U.S. phase I results of taletrectin
Autor:
Steven J. Cohen, Safi Shahda, Colin D. Weekes, Efrat Dotan, Bert H. O'Neil, Shailaja Uttamsingh, Dana Backlund Cardin, Wells A. Messersmith, Ann M. Kapoun, Crystal S. Denlinger, Igor Astsaturov, Robert Joseph Stagg, Heinz-Josef Lenz, Rainer K. Brachmann
Publikováno v:
Clin Cancer Res
Purpose: The recombinant fusion protein ipafricept blocks Wnt signaling, and in combination with gemcitabine and nab-paclitaxel caused tumor regression in xenografts. This phase Ib study evaluated the combination of ipafricept with nab-paclitaxel + g
Autor:
Michael S. Gordon, Naiyer A. Rizvi, Ignacio González-García, Philip Mallinder, Jennifer Cann, Ashish V. Chintakuntlawar, Raid Aljumaily, Helen J. Ross, Shahram Rahimian, Nairouz Elgeioushi, Nathan Standifer, Aung Naing, Crystal S. Denlinger, Nicholas M. Durham, Rakesh Kumar, Ani Sarkis Balmanoukian, Jeffrey R. Infante
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(23)
Purpose: The safety and preliminary efficacy of MEDI1873, an agonistic IgG1 fusion protein targeting glucocorticoid-induced TNF receptor–related protein (GITR), were evaluated in an open-label, first-in-human, phase I, dose escalation study in prev
Autor:
Ghazaleh Eskandari, Uz Stammberger, Hesham M. Amin, Siqing Fu, Samer El Bawab, Sarina Anne Piha-Paul, Rolf Bruns, Daniel V.T. Catenacci, Razelle Kurzrock, Friedhelm Bladt, Gerald Steven Falchook, Pascal Girard, Manja Friese-Hamim, Filip Janku, David S. Hong, Andreas Johne, Manfred B. Klevesath, Wenyuan Xiong
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 6
Purpose: Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the MTD of tepotinib to determine the recommended phase II dose (RP2D). Patients and Methods: Patients received tepotinib orally accor
Autor:
Jay Feingold, Joseph Boni, Mehdi Hamadani, Karin Havenith, David Ungar, Leonard T. Heffner, Paolo Caimi, Brad S. Kahl, Kirit M. Ardeshna, Erin Reid, John Radford, Owen A. O'Connor, Carmelo Carlo-Stella, Shui He, Melhem Solh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(23)
Purpose: ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety and preliminary clinical activity of loncastuximab tesirine
Autor:
Minal A. Barve, Anjla Sood, Sarina Anne Piha-Paul, Dimple A. Modi, Jessica E. Hutti, Sapna Pradyuman Patel, Jasgit C. Sachdev, Bert H. O'Neil, Primo N. Lara, Beibei Hu, Xiaotian Chen, Russell Z. Szmulewitz, Johannes E. A. Wolff, Patricia LoRusso, Kevin J. Freise
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(21)
Purpose:Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET causes apoptosis of cancer cells in vitro. In this first-in-human stu
Autor:
Sophie Callies, Kathleen N. Moore, Volker Wacheck, Johanna C. Bendell, Shubham Pant, Ji Lin, Aaron Fink, Todd M. Bauer, Enaksha R Wickremsinhe, Ricardo Martinez, David M. Hyman, Anna M. Varghese
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(14)
Purpose: The PI3K/mTOR pathway is frequently aberrated in cancer. LY3023414 is a potent and selective ATP-competitive inhibitor of class I PI3K isoforms, mTOR, and DNA-PK. Here we report the dose-escalation results of the first-in-human phase I study